Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) and U.S. Stem Cell (OTCMKTS:USRM – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Valuation and Earnings
This table compares Data Knights Acquisition and U.S. Stem Cell’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Data Knights Acquisition||N/A||N/A||$340,000.00||$0.03||364.67|
|U.S. Stem Cell||$80,000.00||20.67||-$2.86 million||N/A||N/A|
Data Knights Acquisition has higher earnings, but lower revenue than U.S. Stem Cell.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Data Knights Acquisition||0||0||0||0||N/A|
|U.S. Stem Cell||0||0||0||0||N/A|
Institutional and Insider Ownership
78.5% of Data Knights Acquisition shares are held by institutional investors. 23.1% of Data Knights Acquisition shares are held by insiders. Comparatively, 16.7% of U.S. Stem Cell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Data Knights Acquisition has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Comparatively, U.S. Stem Cell has a beta of -0.56, meaning that its stock price is 156% less volatile than the S&P 500.
This table compares Data Knights Acquisition and U.S. Stem Cell’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Data Knights Acquisition||N/A||-4.45%||0.35%|
|U.S. Stem Cell||-3,487.69%||N/A||-2,522.35%|
Data Knights Acquisition beats U.S. Stem Cell on 6 of the 8 factors compared between the two stocks.
About Data Knights Acquisition
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
About U.S. Stem Cell
U.S. Stem Cell, Inc. is a biotechnology company, which engages in the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product, MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.
Receive News & Ratings for Data Knights Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Data Knights Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.